Interim results showed that detalimogene voraplasmid, a non-viral intravesical gene therapy, demonstrated encouraging activity and safety in patients with high-risk, BCG-unresponsive non–muscle-invasive bladder cancer who had already received extensive prior treatment.
Among 125 evaluable patients, 54% achieved a complete response at some point during treatment, and most responses were seen by the first two-month assessment. Researchers also reported durable benefits, with many responders maintaining remission for up to a year. At the April 2026 data cutoff, nearly 97% of participants had avoided progression to muscle-invasive disease, while more than 90% had not required bladder removal surgery.
The therapy may also help address practical challenges in bladder cancer treatment because it can be stored in a standard freezer and administered through a simple catheter procedure in a regular clinic setting without specialized biohazard handling.
Treatment-related side effects occurred in just over half of patients, but most were mild to moderate and resolved quickly. Common symptoms included fatigue, painful urination, urinary urgency, and frequent urination. Serious treatment-related side effects were uncommon, no treatment-related deaths were reported, and very few patients stopped therapy because of adverse events.